Suppr超能文献

微血管损伤在缺血性心肌中的作用和机制。

The role and mechanisms of microvascular damage in the ischemic myocardium.

机构信息

State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asian, Department of Cardiology, the First Affiliated Hospital of Xinjiang Medical University, Clinical Medical Research Institute of Xinjiang Medical University, 137 Liyushan South Road, Urumqi, 830054, China.

Xinjiang Key Laboratory of Medical Animal Model Research, Urumqi, China.

出版信息

Cell Mol Life Sci. 2023 Oct 29;80(11):341. doi: 10.1007/s00018-023-04998-z.

Abstract

Following myocardial ischemic injury, the most effective clinical intervention is timely restoration of blood perfusion to ischemic but viable myocardium to reduce irreversible myocardial necrosis, limit infarct size, and prevent cardiac insufficiency. However, reperfusion itself may exacerbate cell death and myocardial injury, a process commonly referred to as ischemia/reperfusion (I/R) injury, which primarily involves cardiomyocytes and cardiac microvascular endothelial cells (CMECs) and is characterized by myocardial stunning, microvascular damage (MVD), reperfusion arrhythmia, and lethal reperfusion injury. MVD caused by I/R has been a neglected problem compared to myocardial injury. Clinically, the incidence of microvascular angina and/or no-reflow due to ineffective coronary perfusion accounts for 5-50% in patients after acute revascularization. MVD limiting drug diffusion into injured myocardium, is strongly associated with the development of heart failure. CMECs account for > 60% of the cardiac cellular components, and their role in myocardial I/R injury cannot be ignored. There are many studies on microvascular obstruction, but few studies on microvascular leakage, which may be mainly due to the lack of corresponding detection methods. In this review, we summarize the clinical manifestations, related mechanisms of MVD during myocardial I/R, laboratory and clinical examination means, as well as the research progress on potential therapies for MVD in recent years. Better understanding the characteristics and risk factors of MVD in patients after hemodynamic reconstruction is of great significance for managing MVD, preventing heart failure and improving patient prognosis.

摘要

心肌缺血损伤后,最有效的临床干预措施是及时恢复缺血但存活心肌的血液灌注,以减少不可逆心肌坏死、限制梗死面积并预防心功能不全。然而,再灌注本身可能会加重细胞死亡和心肌损伤,这一过程通常被称为缺血/再灌注(I/R)损伤,主要涉及心肌细胞和心脏微血管内皮细胞(CMECs),其特征是心肌顿抑、微血管损伤(MVD)、再灌注心律失常和致命性再灌注损伤。与心肌损伤相比,I/R 引起的 MVD 一直是一个被忽视的问题。临床上,由于冠状动脉灌注无效导致的微血管性心绞痛和/或无复流,在急性血运重建后患者中的发生率为 5-50%。MVD 限制了药物扩散到受损心肌,与心力衰竭的发展密切相关。CMECs 占心脏细胞成分的>60%,其在心肌 I/R 损伤中的作用不容忽视。虽然有很多关于微血管阻塞的研究,但关于微血管渗漏的研究很少,这可能主要是由于缺乏相应的检测方法。在这篇综述中,我们总结了心肌 I/R 期间 MVD 的临床表现、相关机制、实验室和临床检查手段,以及近年来针对 MVD 的潜在治疗方法的研究进展。更好地了解血流动力学重建后患者 MVD 的特征和危险因素,对于管理 MVD、预防心力衰竭和改善患者预后具有重要意义。

相似文献

引用本文的文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验